Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Fineline Cube Jul 13, 2026
Company Deals

InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments

Fineline Cube Jul 13, 2026
Company Deals

PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates

Fineline Cube Jul 10, 2026
Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Fineline Cube Jul 13, 2026
Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Fineline Cube Jul 13, 2026
Company

Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact

Fineline Cube Feb 7, 2023

Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial...

Company

Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth

Fineline Cube Feb 7, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...

Company Drug

Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial

Fineline Cube Feb 7, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...

Company Drug

Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study

Fineline Cube Feb 7, 2023

US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...

Company Deals

Lifetech Partners with Jenscare for Structural Heart Disease Devices

Fineline Cube Feb 7, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare...

Company Drug

Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...

Company

Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results

Fineline Cube Feb 6, 2023

US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...

Company Drug

Sanofi Reports Strong Q4 and Full-Year 2022 Financials with 7% Growth

Fineline Cube Feb 6, 2023

France’s Sanofi (EPA: SAN) released its financial report last week, showing turnover during Q4 and...

Company

Sanner Group Prepares to Open Second Manufacturing Facility in China

Fineline Cube Feb 6, 2023

Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to...

Company

Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi

Fineline Cube Feb 6, 2023

China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...

Digital Medical Device

Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment

Fineline Cube Feb 6, 2023

China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA)...

Company Digital

BeiGene Launches Mental Health Program for Cancer Patients

Fineline Cube Feb 6, 2023

China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...

Company Deals

AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics

Fineline Cube Feb 6, 2023

Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...

Company Drug

Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment

Fineline Cube Feb 6, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Forlong Biotechnology Secures Series A Funding for Protein Drug Development

Fineline Cube Feb 6, 2023

Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...

Company Deals

Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06

Fineline Cube Feb 6, 2023

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...

Company Deals

Haisco Pharmaceutical Announces Public Offering for Clinical Studies

Fineline Cube Feb 6, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...

Company Drug

BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review

Fineline Cube Feb 6, 2023

Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...

Company Drug

JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course

Fineline Cube Feb 6, 2023

Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...

Posts pagination

1 … 593 594 595 … 693

Recent updates

  • Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer
  • Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
  • Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma
  • Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan
  • Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer

Company Deals

Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies

Company Drug

Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma

Company Drug

Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.